DBV Technologies S.A. (DBVT)

NASDAQ: DBVT · IEX Real-Time Price · USD
0.614
-0.014 (-2.20%)
At close: May 22, 2024, 3:59 PM
0.618
+0.004 (0.64%)
After-hours: May 22, 2024, 4:00 PM EDT
-2.20%
Market Cap 137.42M
Revenue (ttm) 14.94M
Net Income (ttm) -79.51M
Shares Out 222.37M
EPS (ttm) -0.44
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 72,643
Open 0.623
Previous Close 0.628
Day's Range 0.605 - 0.630
52-Week Range 0.420 - 2.260
Beta 0.76
Analysts Strong Buy
Price Target 4.50 (+632.9%)
Earnings Date May 7, 2024

About DBVT

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs includes vaccine for the respirato... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2002
Employees 104
Stock Exchange NASDAQ
Ticker Symbol DBVT
Full Company Profile

Financial Performance

In 2023, DBVT's revenue was 15.73 million, an increase of 224.69% compared to the previous year's 4.84 million. Losses were -72.73 million, -24.46% less than in 2022.

Financial numbers in EUR Financial Statements

Analyst Forecast

According to 2 analysts, the average rating for DBVT stock is "Strong Buy." The 12-month stock price forecast is $4.5, which is an increase of 632.90% from the latest price.

Price Target
$4.5
(632.90% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

DBV Technologies Announces Plan to Implement ADS Ratio Change

Châtillon, France, May 17, 2024 DBV Technologies Announces Plan to Implement ADS Ratio Change DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT—CUSIP: 23306J101), a clin...

5 days ago - GlobeNewsWire

DBV Technologies Announces Results of its 2024 Combined General Meeting

Châtillon, France, May 16, 2024 DBV Technologies Announces Results of its 2024 Combined General Meeting Shareholders approved all proposed resolutions DBV Technologies (Euronext: DBV – ISIN: FR0010417...

6 days ago - GlobeNewsWire

DBV Technologies to Participate in Upcoming Investor Conferences

Montrouge, France, May 9, 2024 DBV Technologies to Participate in Upcoming Investor Conferences DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biop...

13 days ago - GlobeNewsWire

DBV Technologies Reports First Quarter 2024 Financial Results and Business Update

Montrouge, France, May 7, 2024 DBV Technologies Reports First Quarter 2024 Financial Results and Business Update VITESSE enrollment on track to screen last patient by Q3 2024 Appointment of Robert Pie...

15 days ago - GlobeNewsWire

Combined General Meeting of May 16, 2024

Châtillon, France, April 25, 2024 Combined General Meeting of May 16, 2024 Procedures for Obtaining Information and Preparatory Documents for the Combined General Meeting DBV Technologies (Euronext: D...

27 days ago - GlobeNewsWire

DBV Technologies announces filing of 2023 Annual Report on Form 10-K and Universal Registration Document

Montrouge, France, March 8, 2024 DBV Technologies announces filing of 2023 Annual Report on Form 10-K and Universal Registration Document DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq ...

2 months ago - GlobeNewsWire

DBV Technologies Reports Full Year 2023 Financial Results and Business Update

Montrouge, France, March 7, 2024 DBV Technologies Reports Full Year 2023 Financial Results and Business Update Advanced Viaskin™ Peanut clinical development programs in peanut-allergic toddlers (1 thr...

2 months ago - GlobeNewsWire

DBV Technologies to Report Full Year 2023 Financial Results and Business Update on March 7, 2024

Montrouge, France, March 4, 2024 DBV Technologies to Report Full Year 2023 Financial Results and Business Update on March 7, 2024 DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Ma...

2 months ago - GlobeNewsWire

DBV Technologies to Participate in Upcoming AAAAI 2024 Congress

Montrouge, France, February 20 2024 DBV Technologies to Participate in Upcoming AAAAI 2024 Congress DBV Technologies (Euronext: DBV – ISIN: FR0010417345 –NASDAQ: DBVT), a clinical-stage biopharmaceuti...

3 months ago - GlobeNewsWire

Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF

AMF Regulated Information Montrouge, France, January 16, 2024 Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq St...

4 months ago - GlobeNewsWire

Top 5 Health Care Stocks That Could Blast Off In December - DBV Technologies (NASDAQ:DBVT), Cigna Group (NYSE:CI)

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Other symbols: CIKTRAMDPDCO
6 months ago - Benzinga

DBV Technologies Announces 2-Year Results from Ongoing Phase 3 Open-Label Extension to the EPITOPE Trial (EPOPEX) of Viaskin™ Peanut in Toddlers

Montrouge, France, November 9, 2023 DBV Technologies Announces 2-Year Results from Ongoing Phase 3 Open-Label Extension to the EPITOPE Trial (EPOPEX) of Viaskin™ Peanut in Toddlers Viaskin Peanut show...

6 months ago - GlobeNewsWire

DBV Technologies to Present New Data at ACAAI 2023

Montrouge, France, November 2, 2023 DBV Technologies to Present New Data at ACAAI 2023 New data to include late-breaking abstract detailing interim 12-month results from the ongoing Phase 3 open-label...

7 months ago - GlobeNewsWire

DBV Technologies Receives Requested Feedback from FDA on Protocol Design Elements for COMFORT Safety Studies and Reports Third Quarter 2023 Financial Results

Montrouge, France, October 31, 2023 DBV Technologies Receives Requested Feedback from FDA on Protocol Design Elements for COMFORT Safety Studies and Reports Third Quarter 2023 Financial Results DBV ha...

7 months ago - GlobeNewsWire

DBV Technologies to Report Third Quarter 2023 Financial Results and Business Update

Montrouge, France, October 27, 2023 DBV Technologies to Report Third Quarter 2023 Financial Results and Business Update DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT...

7 months ago - GlobeNewsWire

DBV Technologies Announces Appointment of Virginie Boucinha as Chief Financial Officer

Montrouge, France, October 16, 2023 DBV Technologies Announces Appointment of Virginie Boucinha as Chief Financial Officer DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: D...

7 months ago - GlobeNewsWire

DBV Technologies to Participate in Upcoming Investor Conference

Montrouge, France, September 5, 2023 D BV Technologies to Participate in Upcoming Investor Conference DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stag...

9 months ago - GlobeNewsWire

DBV Technologies Receives Feedback from FDA on Design Elements for Viaskin Peanut Safety Studies and Reports Second Quarter and Half-Year 2023 Financial Results

GlobeNewswire window.initGradientEffect = function () { } document.addEventListener('DOMContentLoaded', function () { const extendedTableZoomElements = document.querySelectorAll('.extended-table-zoom'...

10 months ago - GlobeNewsWire

DBV Technologies to Report First Half 2023 Financial Results and Provide a Corporate Update

Montrouge, France, July 25, 2023 DBV Technologies to Report First Half 202 3 Financial Results and Provide a Corporate Update DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market...

10 months ago - GlobeNewsWire

DBV Technologies to Participate in Upcoming EAACI Congress 2023

Montrouge, France, June 8, 2023 DBV Technologies to Participate i n Upcoming EAACI Congress 2023 DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage bio...

1 year ago - GlobeNewsWire

DBV Technologies Announces New England Journal of Medicine Publication of Phase 3 EPITOPE Trial Data Evaluating Viaskin™ Peanut in Toddlers

Montrouge, France, May 10, 2023 DBV Technologies Announces New England Journal of Medicine Publication of Phase 3 EPITOPE Trial D ata E valuating Viaskin™ Peanut in Toddlers Th e New England Journal o...

1 year ago - GlobeNewsWire

DBV Technologies Reports First Quarter 2023 Financial Results

Montrouge, France, May 4, 2023 DBV Tech nolo gies Reports First Quarter 2023 Financial Results DBV closes Q1 2023 with cash and cash equivalents of $192.3 million . DBV Technologies (Euronext: DBV – I...

1 year ago - GlobeNewsWire

DBV Technologies Outlines Regulatory Path for Viaskin Peanut in Children 1 – 3 Years After Receiving Pre-BLA Responses from FDA

Montrouge, France, April 19, 2023 D BV Technologies Outlin es Regulatory Path for Viaskin Peanut in Children 1 – 3 Years After Receiving Pre-BLA Responses from FDA The FDA confirmed that the Company's...

1 year ago - GlobeNewsWire

DBV Technologies Announces Results of its 2023 Ordinary and Extraordinary General Meeting

Montrouge, France, April 12, 2023 DBV Technologies Announces Results of its 202 3 Ordinary and Extraordinary General Meeting Shareholders A pprove d A ll P roposed R esolutions DBV Technologies (Euron...

1 year ago - GlobeNewsWire

Ordinary and Extraordinary General Meeting of April 12, 2023

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, will hold its Ordinary and Extraordinary General Meeting (the “General Me...

1 year ago - GlobeNewsWire